Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 21 of 21 results for empagliflozin

  1. Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]

    Discontinued [GID-TA10177]

    Technology appraisal guidance
    Discontinued

  2. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

    Technology appraisal guidance
    Discontinued

  3. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

    NICE guideline
    Published
    12 September 2018
    View recommendations

    Sections for NG106

  4. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Evidence summary
    Published
    11 March 2014

  5. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902

  6. Three new treatment options for type 2 diabetes recommended by NICE

    Tens of thousands of people with type 2 diabetes will be eligible for new treatments under new guidance from NICE.

    News
    Published
    25 May 2016